$CELG News Intuitive Surgical slumps; Facebook extends

New Post Public Reply Private Reply Replies (0) Message Board

Apr 27, 2014 at 12:00 PM

$CELG News

Intuitive Surgical slumps; Facebook extends rally 3:41 p.m. April 9, 2014 - Sue Chang
What ‘Game of Thrones’ can teach you about money 8:30 a.m. April 5, 2014 - Wallace Witkowski
Biotechs, bonds and more from the 'tempest in a microsecond' 8:32 a.m. April 2, 2014 - Shawn Langlois
Play-it-safe stock investors may take some risk on jobs 8:31 a.m. March 30, 2014 - Wallace Witkowski
Nasdaq pullback rife with opportunity 2:07 p.m. March 25, 2014 - The Trading Deck
44 stocks on takeover target radar: Morgan Stanley 12:48 p.m. March 25, 2014 - blogs.marketwatch.com
Biotech comeback stalls as Wall Street starts to worry 12:45 p.m. March 25, 2014 - Russ Britt
Biotech has second straight sell-off; sector mutual funds take it on chin 10:40 a.m. March 24, 2014 - Russ Britt
Biotech's Friday selloff: Are sector bears growling or just stretching? 5:08 p.m. March 21, 2014 - Russ Britt
The Nasdaq has a message to deliver 1:57 p.m. March 20, 2014 - The Trading Deck
Aeropostale slides; Liberty Media drops Sirius plan 4:16 p.m. March 14, 2014 - Sue Chang
UK drug rejection, patent concerns take a bite out of Celgene shares 1:33 p.m. March 14, 2014 - Russ Britt
From every angle, technicals point to richer stocks 2:26 p.m. March 11, 2014 - The Trading Deck
Winning approval for new drugs may get harder, analyst warns 4:56 p.m. Feb. 28, 2014 - Russ Britt
The market puts a few feathers in its cap 2:58 p.m. Jan. 23, 2014 - The Trading Deck
Dow industrials suffer worst drop since Sept. 20: Stock market live blog recap 5:41 p.m. Jan. 13, 2014 - blogs.marketwatch.com
Celgene's 2014 guidance falls below analyst views 1:19 p.m. Jan. 13, 2014 - MarketWatch.com
Clovis Oncology, seen as 'next ICPT,' jumps 5% 10:47 a.m. Jan. 13, 2014 - Victor Reklaitis
Intercept, Celgene on move amid J.P. Morgan event 10:20 a.m. Jan. 13, 2014 - Victor Reklaitis
Epizyme shares surge 65% after cancer therapy hits milestone 12:06 p.m. Jan. 7, 2014 - Russ Britt

Disappointments? Think Opportunities; Miracle Drug May Be Ailing Gilead: Jim Cramer's Best Blogs 6:00 a.m. April 26, 2014 - TheStreet.com
Celgene working today amid upgrade 3:27 p.m. April 25, 2014 - Seeking Alpha
3 Drugs Stocks Moving The Industry Upward 1:03 p.m. April 25, 2014 - TheStreet.com
Will This Analyst Upgrade Help Celgene (CELG) Stock Today? 9:33 a.m. April 25, 2014 - TheStreet.com
Analysts' Actions: CELG CUDA FITB TWC WFC 8:13 a.m. April 25, 2014 - TheStreet.com
Celgene Corporation (CELG): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report 8:00 a.m. April 25, 2014 - Zacks.com
Cramer's Mad Money - Revenge Of The Nerds (4/24/14) 6:45 a.m. April 25, 2014 - Seeking Alpha
'Mad Money' Lightning Round: United Rentals Is Really Good 6:00 a.m. April 25, 2014 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Nerds Rule 8:19 p.m. April 24, 2014 - TheStreet.com
Gilead, Alexion, Biogen, Or Celgene: 1 Mindboggling Metric Identifies The Best Value! 4:57 p.m. April 24, 2014 - Seeking Alpha
Celgene Corporation's CEO Discusses Q1 2014 Results - Earnings Call Transcript 4:17 p.m. April 24, 2014 - Seeking Alpha
Celgene Earnings Grow Year Over Year in Q1 - Analyst Blog 1:27 p.m. April 24, 2014 - Zacks.com
June 6th Options Now Available For Celgene (CELG) 12:14 p.m. April 24, 2014 - TheStreet.com
Jim Cramer Breaks Down Apple (AAPL), Caterpillar (CAT) and American Airlines Group's (AAL) Earnings 12:04 p.m. April 24, 2014 - TheStreet.com
Jim Cramer's Stop Trading: CELG 11:06 a.m. April 24, 2014 - TheStreet.com
Alexion, Celgene Report Contrasting Q1 Earnings 10:39 a.m. April 24, 2014 - Investors Business Daily
Stock Market News for April 24, 2014 - Market News 10:06 a.m. April 24, 2014 - Zacks.com
Celgene licenses Crohns treatment for at least $710M 8:43 a.m. April 24, 2014 - Seeking Alpha
Celgene's Revenue Rises on Higher Sales of Cancer Drug Revlimid 8:31 a.m. April 24, 2014 - The Wall Street Journal Interactive Edition
More on Celgene Q1 results 8:04 a.m. April 24, 2014 - Seeking Alpha

Celgene Corporation to Present at Investor Conferences in May 8:30 a.m. April 25, 2014 - BusinessWire - BZX
Drug Approvals, Quarterly Earnings Releases, and Stock Price Updates - Analyst Notes on Merck, Johnson & Johnson, UnitedHealth, Celgene and GW 8:00 a.m. April 25, 2014 - PR Newswire - PRF
Celgene Acquires Late-Stage Product for Crohn’s Disease and Other Gastrointestinal Disorders 7:33 a.m. April 24, 2014 - BusinessWire - BZX
Upcoming Earnings Announcements -- Research on Superior Energy Services, Celgene, Penn National Gaming, and PerkinElmer 12:32 p.m. April 22, 2014 - PR Newswire - PRF
Healthcare Companies Report Product Availability, Earning Release Schedules, Event, and Stock Movements - Analyst Notes on Celgene, Vanda, Chelsea Therapeutics, Neurocrine Biosciences, and USANA 8:00 a.m. April 14, 2014 - PR Newswire - PRF
BlackBerry CEO May Consider Exiting Handset Business; Celgene Corporation Favored over Natco in Pre-trial 12:43 a.m. April 10, 2014 - ACCESSWIRE
Coverage of Biotech Equities -- Research on Arena Pharma, Celgene, PDL BioPharma, and Hemispherx Biopharma 1:20 p.m. April 8, 2014 - PR Newswire - PRF
Celgene Corporation Sued by Mylan Inc.; GRUBHUB Soars on its First Day of Trading 12:10 a.m. April 7, 2014 - ACCESSWIRE
BetterInvesting Magazine Releases June Stock To Study And Undervalued Stock Choices For Investors' Informational And Educational Use 4:15 p.m. April 4, 2014 - PR Newswire - PRF
Healthcare Companies Report Transactions, Appeals, New Research Findings and Stock Movements - Analyst Notes on Johnson & Johnson, Teva, Celgene, Cara Therapeutics, and OncoMed Pharmaceuticals 8:00 a.m. April 3, 2014 - PR Newswire - PRF
Critical Alerts For News Corp, Gold SPDR, McDonalds, Trina Solar, and Celgene Released By InvestorsObserver 9:31 a.m. April 1, 2014 - PR Newswire - PRF
Celgene Corporation to Announce First Quarter 2014 Results on April 24, 2014 8:30 a.m. April 1, 2014 - BusinessWire - BZX
Adding Multi-Media Materials: OTEZLA® (apremilast) – First Oral Therapy Approved by the U.S. Food and Drug Administration for the Treatment of Adults with Active Psoriatic Arthritis 4:23 p.m. March 24, 2014 - BusinessWire - BZX
Acceleron, Celgene and Collaborators Announce Two Publications in Nature Medicine Describing Sotatercept and ACE-536 Therapeutic Potential in Beta-thalassemia and Myelodysplastic Syndromes 7:30 a.m. March 24, 2014 - BusinessWire - BZX
Oral OTEZLA® (apremilast) Demonstrated Clinically Meaningful and Sustained Improvements in Skin, Nail and Scalp of Adult Patients with Moderate to Severe Plaque Psoriasis 3:05 p.m. March 23, 2014 - BusinessWire - BZX
OTEZLA® (apremilast) – First Oral Therapy Approved by the U.S. Food and Drug Administration for the Treatment of Adults with Active Psoriatic Arthritis 3:40 p.m. March 21, 2014 - BusinessWire - BZX
Momentum Indicators for Health Care Equities -- Research on Arena Pharma, Hemispherx Biopharma, PDL BioPharma and Celgene 8:16 a.m. March 20, 2014 - PR Newswire - PRF
First-of-Its-Kind Multinational Survey Confirms Psoriasis and Psoriatic Arthritis Patients Are Frequently Undertreated or Not Treated at All 8:02 a.m. March 20, 2014 - BusinessWire - BZX
Celgene Reiterates Commitment to Improving Pancreatic Cancer Care in Europe, Through Significant Research and Patient Support Initiatives 4:18 a.m. March 19, 2014 - BusinessWire - BZX
Conference Schedules, Upcoming Marathon Applications, Revised Guidance, and Acquisitions - Analyst Notes on Celgene, Medtronic, Alexion, Quest Diagnostics, and Illumina 8:00 a.m. March 14, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cyngn: A Deep Dive into Its Robust 24-Patent Portfolio

Cyngn's Growing Patent Portfolio: A Robust Defense Ah, Cyngn Inc., the hotshot in AI-powered autonomous vehicle tech, is flexing its muscles with a solid 24-patent stash. We're talking about a company that's not messing around, racking these up since they decided to dive head-first into solving the brain-busting problems of the industrial sector. Their strategy? Build and...

Sarepta Under Scrutiny: KSF's Investigation Deepens

A Troubling Chapter for Sarepta Therapeutics It's not every day that a company's dirty laundry gets hung out for all to see, especially when we're talking about Sarepta Therapeutics, a player in the rare disease treatment space. But that's exactly where we find ourselves this fine day—a bit like kicking a hornet's nest, if you ask me. Led by the former Louisiana...

Bamboo Unveils Tailored Home Insurance for Texans

Adapt or Get Left Behind: The Texas Insurance Scene In a world where costs are ballooning and the pressure on the wallet grows heavier, here comes Bamboo Insurance swinging into Texas like a hopeful knight. This plucky insurer is rolling out the Texas Essential Homeowner Program, a highly adaptable, admitted policy that promises to put some power back into the hands of...

Baseus Debuts Innovations at IFA 2026: Earbuds to Security

Baseus Pumps New Blood into Tech Gadgets Well, if you're looking for some fresh tech pumping in from Berlin, Baseus tossed out some intriguing gizmos at IFA 2026 that'll perk up your ears. We're looking at an evolution from a brand that's clawed its way from everyday accessories to a full-blown tech ecosystem—pretty ambitious, if you ask me. Baseus isn't playing small...

Beauty Industry's $56B Boom: Trends and Innovations

A Whopping $56 Billion Beauty Surge U.S. beauty sales have jumped by 7%, translating into a dizzying $56 billion 'feel-good effect' in the industry. People are shelling out for products that make them look and feel their best. This isn't just about vanity—consumers are investing in self-care and wellness, a trend shaping what we see on the vanity counter. Every spritz...

Exemplar Luxury Group Taps Gretchen Koback Pursel

Changing the Game with a New Chief People Officer There’s an old saying in retail: talent rules everything. Well, Exemplar Luxury Group is doubling down on this with its appointment of Gretchen Koback Pursel as Chief People Officer. Set to take the reins on September 28, Pursel brings an impressive resume chock-full of luxury and innovative transformations from big...

Curaleaf Expands in Florida Amid Rising Cannabis Demand

Curaleaf's Bold Moves in Florida's Ganja Gold Rush Fresh out of the gate, Curaleaf is saddling up for a wild ride into Florida's cannabis frontier. They've just thrown open the doors of their latest dispensary in Riverview, cranking their statewide count up to 77. Now, isn’t that something? If you're tracking these folks, you know that bringing their nationwide total to...

Inturai Ventures Closes Final Tranche with a Twist

Wrapping Up a Wild Ride in the Investment Arena Markets are a fickle friend, and today we've got Inturai Ventures calling it a day on their latest cash grab. They've locked the final tranche of their private placement, pulling in an aggregate $963,713.70. Feels like they're counting pennies in this venture, but every cent counts when your aim is to shake up industries...

Local Climate Resilience Gains Urgency in the Southwest

Local Impact Means Taking Climate Change Personally If you haven't felt it yet, you will. Climate change isn't just a global headline anymore—it's a daily reality that’s reshaping life where you stand. David W. DuBois, New Mexico's top climatologist, is sounding the alarm this time on the new Net Zero Speaks episode, saying it's on us to use local climate knowledge to...

Labcorp Faces Lawsuit: Wiretapping Accusations Surface

Labcorp's Legal Tangle Unveiled One minute you're on Labcorp's website searching for medical info, the next you're caught up in a class-action legal whirlwind. Legal drama is not on any patient’s checklist, but here we are, with Labcorp knee-deep in some serious allegations. The crux of the matter points to alleged wiretapping violations, with claims that Labcorp,...